ACP
GSK icon

Ashfield Capital Partners’s GSK GSK Stock Holding History

Ashfield Capital Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,254
Closed -$1.28M – 252
2017
Q3 		$1.28M Sell
25,254
-1,709
-6% -$86.7K 0.17% 124
2017
Q2 		$1.45M Sell
26,963
-1,449
-5% -$77.2K 0.2% 116
2017
Q1 		$1.5M Buy
28,412
+2,062
+8% +$105K 0.21% 114
2016
Q4 		$1.27M Sell
26,350
-2,536
-9% -$125K 0.12% 129
2016
Q3 		$1.56M Buy
28,886
+16,928
+142% +$928K 0.13% 120
2016
Q2 		$648K Buy
11,958
+1,596
+15% +$84.1K 0.05% 175
2016
Q1 		$525K Sell
10,362
-1,716
-14% -$85.5K 0.04% 185
2015
Q4 		$609K Sell
12,078
-5,408
-31% -$276K 0.04% 187
2015
Q3 		$840K Sell
17,486
-1,522
-8% -$79.2K 0.05% 170
2015
Q2 		$990K Sell
19,008
-857
-4% -$48.3K 0.05% 164
2015
Q1 		$1.15M Buy
19,865
+1,671
+9% +$95.8K 0.06% 154
2014
Q4 		$972K Buy
18,194
+5,040
+38% +$282K 0.05% 167
2014
Q3 		$756K Buy
13,154
+622
+5% +$38.1K 0.04% 189
2014
Q2 		$838K Buy
12,532
+2,148
+21% +$145K 0.04% 176
2014
Q1 		$694K Hold
10,384
– – 0.03% 181
2013
Q4 		$693K Buy
10,384
+800
+8% +$51.9K 0.03% 179
2013
Q3 		$601K Buy
9,584
+1,691
+21% +$109K 0.03% 183
2013
Q2 		$493K Buy
+7,893
New +$501K 0.03% 184

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ashfield Capital Partners's GSK Position: Q4 2017 in Review

Ashfield Capital Partners sold out of GSK (GSK) in Q4 2017, closing a stake of 25,254 shares — an estimated $1.28M sold.

Ashfield Capital Partners first reported a position in GSK in Q2 2013 and held it in 18 quarters. The position peaked at $1.56M in Q3 2016. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

  • Ashfield Capital Partners reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
  • Ashfield Capital Partners sold 25,254 GSK shares in Q4 2017, an estimated $1.28M.
  • Ashfield Capital Partners first reported a position in GSK in Q2 2013 and held it in 18 quarters.
  • Ashfield Capital Partners's GSK position peaked at $1.56M in Q3 2016.
  • 763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on Ashfield Capital Partners's 13F filing for Q4 2017, filed 13 Feb 2018.